Medivolve announces AGM results and close of actions for debt transaction

TORONTO, 22 November 2021 / CNW / – Medivolve, Inc. (“Medivolve“or the”Society“) (NEO: MEDV) (OTC: COPRF) (FRA: 4NC), reports, in accordance with the policies of the NEO Exchange, that the candidates listed in the management information circular dated 22 October 2021 for the Annual and Extraordinary Meeting of Shareholders of the Company 2021 (the “Meeting“) were elected directors of the Company. 14.12% of all issued and outstanding shares of the Company were represented at the Meeting.

Medivolve, Inc. logo (CNW Group / Medivolve Inc.)

Detailed results of the vote for the election of directors held at the General Meeting of 22 November 2021, in Toronto, Ontario are set out below.

Election of directors

The shareholders approved the election as directors of the persons listed below, on the basis of the following vote.

Candidates for the Board of Directors

% of votes for

% of votes retained

Dr Beverly Richardson



Daniyal Baizak



Wen Ye



Shareholders at the annual meeting also approved the appointment of the Company’s auditors, McGovern Hurley LLP, the re-approval of the Company’s stock option plan and a consolidation of the Company’s common shares on the basis from a maximum of 15 to 1.

Medivolve’s Board of Directors would like to express its gratitude to its shareholders for their continued support.

Debt actions

The Company also announces that it has closed the previously announced settlement of $ 441,000 of its cash debt owed to a creditor through the issuance of 6,300,000 common shares of the Company (the “”Ordinary actions“) at an effective price per share of $ 0.07. In accordance with applicable securities laws, the issued common shares are subject to a hold period of four months and one day.

About Medivolve, Inc.

Medivolve, Inc. (NEO: MEDV; OTC: COPRF; FRA: 4NC) is a healthcare technology company that seeks to reinvent the US healthcare system by leveraging a bespoke telehealth platform, diagnostic network clinical and data-driven AI framework to improve patient care.

The company was born out of the health crisis; to rethink, relearn and, ultimately, reinvent a better functioning of the health system. Our network of retail collection sites play a critical role in recovery by giving all Americans access to fast, accurate, and inexpensive clinical services when and where they need it. These centers will also play a central role in diagnostic tests, vaccinations and other point-of-care services. We develop disruptive technologies to make it easier and faster to identify, treat and prevent medical problems. In doing so, we strive to give patients a holistic and empowered view of their personal health.

Our long-term mission is to permanently solve the systemic problems of the country’s fragmented, overly complex and costly healthcare system. Medivolve’s next phase of growth is to rotate the model and put the pieces together to create a profitable, SaaS-based healthcare technology business. We bring data-driven clinical diagnostics, physician referrals, and prescription drugs directly to people, all powered by a single, streamlined technology network. A powerful and singular goal unites our team: to harness the transformative power of technology to create healthier lives.

Backed by a bespoke AI-driven platform, we are developing a stealth system that constantly gets smarter, takes the guesswork out of diagnoses, and immediately reports critical health issues to deliver an unmatched level of personalization for every patient. We are committed to pushing the boundaries of what is possible, not only for our company and our shareholders, but for physicians and patients and the future of healthcare. We strive for never-before-seen continuity of care, a game changer for our business and the patients in the communities we serve.

Caution regarding forward-looking information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements regarding Medivolve’s pursuit of disruptive technologies, breakthrough innovations, and proprietary partnerships to help combat COVID-19 and the merits or potential returns of such lawsuits. Generally, forward-looking information can be identified by the use of forward-looking terms such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “expected”. , “Estimates”, “anticipates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of these words and expressions or declares that certain actions, events or results “Could”, “could”, “could”, “could” or “will be taken”, “occur” or “be reached”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors which may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially. different from those expressed or implied by such forward-looking information, including, but not limited to: receipt of necessary approvals; general business, economic, competitive, political and social uncertainties; the continued spread of COVID-19; labor disputes and shortages; and other risks of the medical industry. Although the Company has attempted to identify important factors which could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated or planned. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Therefore, readers should not place undue reliance on forward-looking information. The Company does not undertake to update forward-looking information, except in accordance with applicable securities laws.



View original content to download multimedia:

SOURCE Medivolve Inc.



View original content to download multimedia:

Comments are closed.